DO CANCER CLINICAL TRIAL POPULATIONS TRULY REPRESENT CANCER PATIENTS? A COMPARISON OF OPEN CLINICAL TRIALS TO THE CANCER GENOME ATLAS

Autor: Nophar Geifman, Atul J. Butte
Přispěvatelé: Altman, Russ B, Dunker, A Keith, Hunter, Lawrence, Klein, Teri E, Ritchie, Marylyn D
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Oncology
Male
Databases
Factual
Colorectal cancer
Disease
Kaplan-Meier Estimate
Bioinformatics
6.9 Resources and infrastructure (treatment evaluation)
0302 clinical medicine
Neoplasms
Databases
Genetic
030212 general & internal medicine
Precision Medicine
Cancer
Clinical Trials as Topic
Medical research
Colo-Rectal Cancer
030220 oncology & carcinogenesis
Female
Colorectal Neoplasms
medicine.medical_specialty
6.9 Resources and infrastructure
Clinical Trials and Supportive Activities
Breast Neoplasms
03 medical and health sciences
Databases
Breast cancer
Atlases as Topic
Genetic
Clinical Research
Internal medicine
Cancer genome
Breast Cancer
medicine
Genetics
Humans
Genetic Testing
Factual
business.industry
Human Genome
Evaluation of treatments and therapeutic interventions
Prostatic Neoplasms
Computational Biology
medicine.disease
Precision medicine
Clinical trial
Pancreatic Neoplasms
Good Health and Well Being
business
Digestive Diseases
Zdroj: Geifman, N; & Butte, AJ. (2016). DO CANCER CLINICAL TRIAL POPULATIONS TRULY REPRESENT CANCER PATIENTS? A COMPARISON OF OPEN CLINICAL TRIALS TO THE CANCER GENOME ATLAS. PACIFIC SYMPOSIUM ON BIOCOMPUTING 2016, 309-320. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/3b11j8x2
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, vol 21
PSB
Popis: Open clinical trial data offer many opportunities for the scientific community to independently verify published results, evaluate new hypotheses and conduct meta-analyses. These data provide a springboard for scientific advances in precision medicine but the question arises as to how representative clinical trials data are of cancer patients overall. Here we present the integrative analysis of data from several cancer clinical trials and compare these to patient-level data from The Cancer Genome Atlas (TCGA). Comparison of cancer type-specific survival rates reveals that these are overall lower in trial subjects. This effect, at least to some extent, can be explained by the more advanced stages of cancer of trial subjects. This analysis also reveals that for stage IV cancer, colorectal cancer patients have a better chance of survival than breast cancer patients. On the other hand, for all other stages, breast cancer patients have better survival than colorectal cancer patients. Comparison of survival in different stages of disease between the two datasets reveals that subjects with stage IV cancer from the trials dataset have a lower chance of survival than matching stage IV subjects from TCGA. One likely explanation for this observation is that stage IV trial subjects have lower survival rates since their cancer is less likely to respond to treatment. To conclude, we present here a newly available clinical trials dataset which allowed for the integration of patient-level data from many cancer clinical trials. Our comprehensive analysis reveals that cancer-related clinical trials are not representative of general cancer patient populations, mostly due to their focus on the more advanced stages of the disease. These and other limitations of clinical trials data should, perhaps, be taken into consideration in medical research and in the field of precision medicine.
Databáze: OpenAIRE
Externí odkaz: